NASDAQ: HRMYHarmony Biosciences Holdings Inc Stock
$28.93-0.30 (-1.03%)
Updated Apr 25, 2024
HRMY Price
$28.93
Fair Value Price
N/A
Market Cap
$1.64B
52 Week Low
$18.61
52 Week High
$39.27
P/E
13.33x
P/B
3.52x
P/S
3.3x
PEG
0.32x
Dividend Yield
N/A
Revenue
$582.02M
Earnings
$128.85M
Gross Margin
79.2%
Operating Margin
33.87%
Profit Margin
22.1%
Debt to Equity
0.74
Operating Cash Flow
$219M
Beta
0.91
Next Earnings
May 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A
HRMY Overview
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how HRMY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HRMY ($28.93) is trading below its intrinsic value of $43.85, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HRMY is good value based on its earnings relative to its share price (13.33x), compared to the US market average (40.97x)
P/E vs Market Valuation
HRMY is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more HRMY due diligence checks available for Premium users.
Be the first to know about important HRMY news, forecast changes, insider trades & much more!
HRMY News
Valuation
HRMY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
13.33x
Industry
15.41x
Market
40.97x
HRMY is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
HRMY is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
HRMY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.52x
Industry
5.8x
HRMY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HRMY price to earnings growth (PEG)
For valuing profitable companies with growth potential
HRMY is good value based... subscribe to Premium to read more.
PEG Value Valuation
HRMY's financial health
Profit margin
Revenue
$168.4M
Net Income
$26.6M
Profit Margin
15.8%
HRMY's Earnings (EBIT) of $197.15M... subscribe to Premium to read more.
Interest Coverage Financials
HRMY's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$811.4M
Liabilities
$344.5M
Debt to equity
0.74
HRMY's short-term assets ($451.07M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HRMY's short-term assets ($451.07M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HRMY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
HRMY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$76.7M
Investing
-$36.1M
Financing
-$53.5M
HRMY's operating cash flow ($219.39M)... subscribe to Premium to read more.
Debt Coverage Financials
HRMY vs Biotech Stocks
Harmony Biosciences Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.